Cosmetic Standards & Regulations Explained for Barrier Repair & Sensitive Skin

Key Technical Parameters #

Barrier repair and sensitive skin products sit in a regulatory grey zone that catches brands off guard more often than almost any other category. The products look cosmetic on the surface but make claims that brush against drug territory in multiple markets simultaneously. Where a product lands on the cosmetic-drug spectrum determines your entire compliance burden, your labeling rules, and in some markets, your factory certification requirements. The teams who navigate this well aren’t necessarily working with better formulas. They brief us on the regulatory endpoint first, and we build backward from there.

Reading the Market Map: What “Cosmetic” Actually Means Across Four Regulatory Systems #

The foundational problem with barrier repair and sensitive skin products is that each major market draws the cosmetic-drug boundary at a different point, and none of them draw it in exactly the same place.

Under EU Cosmetics Regulation 1223/2009, a barrier cream that “restores the skin’s natural protective function” is cosmetic. The same claim in the US, phrased as “treats dry skin caused by eczema,” activates FDA OTC drug status under the Skin Protectant monograph. In China, the NMPA Cosmetic Regulation classifies products into ordinary and special-use cosmetics, and anything claiming to rebuild or repair skin barrier function at a functional level may be reviewed as a special-use registration. That distinction matters enormously because special-use registration in China takes 6–12 months longer and requires local clinical safety data.

Japan and South Korea operate their own frameworks (quasi-drugs and functional cosmetics, respectively), but the four markets our brand partners most commonly brief us for are EU, US, China, and the combined GCC/Southeast Asian export block. Each one requires a different documentation stack, and the intersection is where projects stall.

Here’s where the divergence becomes operational, not just theoretical:

The table above covers the four frameworks we deal with most regularly. Blank cells in a brand’s compliance matrix almost always mean untested territory, and that surfaces during NMPA registration or port customs checks, not before.

The Standard Everybody References and Almost Nobody Reads Correctly #

ISO 16128 gets cited in marketing briefs constantly. “Natural index above 0.9.” “98% natural origin.” It shows up in concept decks before anyone has run the calculation. In practice, the ISO 16128-1 and 16128-2 standard defines natural and natural-derived origin indices using a specific formula that treats processing steps differently depending on how far a material is chemically modified from its source. A fermentation-derived ingredient like sodium hyaluronate can score 1.0 under ISO 16128. A plant-derived emulsifier that’s been ethoxylated scores closer to 0.5. Neither number is inherently better for a sensitive skin product. They’re just numbers.

The compliance pitfall we see repeatedly: brands arrive with a finished concept and a “natural 95%” claim, and when we run the actual ISO 16128 index calculation on the full INCI list, the number comes in at 0.78. Not because the formula is synthetic-heavy, but because a few mid-list functional ingredients like carbomer or PEG-type emulsifiers pull the index down. At that point, the claim either needs to be revised or the formula does, and one of those conversations is easier than the other.

For barrier repair specifically, ISO 16128 creates a secondary problem: the actives that demonstrably work (ceramides NP/AP/EOP, cholesterol, free fatty acids) are mostly synthetic or semi-synthetic by origin. In our formulation lab, ceramide NP synthesized via fermentation can achieve an ISO 16128 natural origin index of around 0.7 depending on the synthesis route and supplier documentation. If a brand is building around a genuine natural positioning, ceramide concentrations above 2% in the formula may start dragging the total index below whatever threshold the brand has committed to on-pack. We flag this at kickoff. Usually the brand hadn’t modeled it.

ISO 11930 for preservative efficacy is a different story. This one is genuinely mandatory for EU market entry, referenced in EU Cosmetics Regulation 1223/2009 Annex I Article 10 as part of the Product Safety Report requirements, and the pass criteria are specific: for Criterion A, less than a 2.0 log reduction from initial count at 14 days for bacteria, and for Criterion B (accepted for leave-on skin products), no increase from the 14-day count. In our lab, roughly 40% of first-draft barrier repair formulas fail ISO 11930 at Criterion A when they use low-concentration preservative systems to meet clean beauty positioning. We usually pass at Criterion B, but that requires documentation in the CPSR and sometimes a note from the Responsible Person.

The Compliance Gap That Derails Multi-Market Launches #

Most product developers we work with want a single formula that ships into EU, US, and China simultaneously. That is achievable but it requires making decisions that reduce optionality, and most brands don’t price that in during concept.

Here’s the core tension. The FDA OTC Skin Protectant pathway requires petrolatum at ≥30% if it’s the sole active, or colloidal oatmeal at 0.003–0.33% as an alternative. Both concentrations anchor the formula in a way that affects texture significantly. A 30% petrolatum base makes an elegant lightweight serum essentially impossible. Colloidal oatmeal at OTC levels is functional but creates sensory and stability challenges of its own.

A 2022 split-face clinical study (n=46, 8 weeks) evaluating a colloidal oatmeal barrier repair cream at 0.1% versus an identically formulated placebo showed a 24% improvement in TEWL values in the active arm versus 9% in placebo, measured by Tewameter TM300. The data was used to support an OTC drug claim in the US. That same formula, in EU, requires no OTC designation but the CPSR must document the colloidal oatmeal source, particle size, and that Annex III restricted substances (specifically some botanical co-extractives) are within limits. In China, that formula would require NMPA registration as a special-use product if the “barrier repair” function claim is retained, meaning the 6–12 month pathway and locally conducted safety testing.

Three different documentation packages. One formula.

Brands that plan for this from day one — deciding which claim hierarchy to anchor to, and which markets to pursue first — launch 4–6 months faster than brands that try to retrofit compliance after the formula is locked. This sounds obvious. In practice, almost nobody does it upfront. The conversation about regulatory strategy usually starts after the first formula is already in accelerated stability.

The other issue is INCI naming via PCPC Guidelines. China’s NMPA now requires that INCI names match the Catalogue of Existing Cosmetic Ingredients (CIEC) exactly, and certain INCI names acceptable under PCPC conventions are not present in the CIEC, or exist under a different name. Sphingolipids are a recurring example. Several ceramide types have INCI names that are standardized in the US/EU but require specific documentation cross-referencing in China registration. We maintain an internal AVL (Approved Vendor and INCI Verification List) that we cross-check against CIEC before finalizing any ingredient that’s outside the standard glycerin-water-hyaluronic acid tier.

Prevention: What to Specify Before the Formula Exists #

The brands that clear multi-market compliance with the least friction give us four things at kickoff, before we’ve touched a beaker.

Target markets ranked by priority. If China is market one, we need to know before we select ceramide source or preservative. If EU is market one and US is market two, the claim hierarchy is different and the CPSR scope changes.

Claim ceiling. “Hydrates” is straightforward. “Restores barrier function” needs substantiation. “Treats eczema-prone skin” is OTC drug territory in the US and requires a different project pathway entirely. We need the claim ceiling agreed before raw material selection.

Natural index target, if any. If the brand has committed to an on-pack “98% natural origin” claim, we need to model that before actives selection, not after.

Packaging material. This sounds like a manufacturing detail, but preservative efficacy testing and packaging compatibility interact directly. The ISO 11930 test is run in the final container. Switching from HDPE to a metallic laminate tube at month four of development can invalidate a passing PET. Our QC-F14 form (the packaging compatibility sign-off document we issue before stability is initiated) exists specifically because we’ve had this failure mode enough times to formalize it.

Request from your OEM partner early: a draft CPSR scope document (for EU) or a preliminary NMPA ingredient pre-screening report (for China). If they can’t produce either within the first two weeks of a project, that tells you something about their regulatory capability.

Formulation Notes for Brand Partners #

When you brief us on a barrier repair or sensitive skin product, the first questions we ask are: what markets, in what order, and what’s the claim on pack? Those three answers change everything downstream.

The most common brief mistake we see is arriving with a claims deck that was written for EU and a formula concept that has US OTC actives baked in, without realizing those two paths require different documentation, different factories in some cases, and different lead times. A petrolatum-based OTC skin protectant for the US and a ceramide-based cosmetic barrier cream for EU can use overlapping raw materials but they are different regulatory projects. Treating them as one project until month three is the fastest way to miss a launch window.

What we need from you: confirmed market priority list, on-pack claim text (exact wording if possible), any natural origin index commitments, format and pack type, and target consumer skin type. If you have existing safety data or prior art from another market, share it — it sometimes reduces our clinical burden.

Timeline: lab samples in 2–3 weeks from brief confirmation, accelerated stability (40°C/75% RH, 8 weeks) initiated concurrently with sample review, 24-month real-time stability started at the same time. ISO 11930 preservative efficacy and dermatologist tolerance testing typically run weeks 4–6 in parallel. For China NMPA pathway, factor in an additional 4–6 weeks for ingredient pre-screening and 8–12 months for full registration.

Frequently Asked Questions #

We want to use “barrier repair” in our product name — is that a cosmetic claim everywhere?
A: Not universally. In the EU it functions as a cosmetic claim provided you have supporting data in the CPSR. In China, depending on how the full label reads and how prominently the claim features, NMPA reviewers have flagged “barrier repair” products for special-use classification review. The safer path for China is “moisturizing and nourishing” as the primary claim, with barrier language in secondary copy.

What ISO 16128 natural index do our ceramide actives get?
A: It depends on the synthesis route and how your supplier documents origin. Fermentation-derived ceramide NP typically scores around 0.7 under ISO 16128-2, while plant-extracted phytosphingosine scores closer to 0.9. If your formula leans on synthetic ceramides above 2% total concentration, model the full formula index before committing to any on-pack natural percentage claim.

Our EU Responsible Person says we need ISO 11930 Criterion A, but that’s hard to pass with our preservative system. Can we use Criterion B?
A: Criterion B is accepted for cosmetic products in the EU — EU Cosmetics Regulation 1223/2009 doesn’t mandate Criterion A for leave-on products. The catch is that your CPSR safety assessor needs to document the rationale, and some retailers (particularly pharmacy chains in France and Germany) run their own supplier audits and flag Criterion B passes. It’s a real compliance grey zone. We’ve had formulas pass for direct-to-consumer and then get queried by a pharmacy buyer. Know your retail channel before deciding.

What’s your MOQ for a barrier repair moisturizer going through NMPA registration, and how long does the process take?
A: For an NMPA ordinary cosmetic (if the claim structure qualifies), pilot batch MOQ starts at 200 kg, production MOQ at 500 kg. For special-use registration, the clinical data package alone adds 8–12 months to the timeline from brief confirmation. Full registration to shelf for China special-use is realistically 18–24 months total. We recommend starting NMPA paperwork in parallel with formula development, not after it.

Should we run our barrier cream as an OTC drug in the US or keep it cosmetic?
A: That depends entirely on the claim. If you want to say “relieves dry skin due to eczema,” you need the OTC Skin Protectant Monograph pathway and a compliant active (petrolatum ≥30% or colloidal oatmeal 0.003–0.33%). If your claim is “intensely moisturizes dry, sensitive skin,” you’re cosmetic and your formula freedom is much broader. The OTC pathway costs more, takes longer, and constrains your formula significantly. The clinical data we referenced from a 2022 study (n=46, 8 weeks, 24% TEWL improvement) was generated specifically to support OTC positioning. Most brands we work with choose the cosmetic path and write claims that stay inside it, unless the eczema-adjacent market positioning is central to the brand story.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.